This trial is conducted in Europe. The aim of this trial is to evaluate the blood glucose-lowering effect of NN5401 (insulin degludec/insulin aspart (IDegAsp)) in subjects with type 2 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
39
0.4 U/kg body weight injected subcutaneously (under the skin) once
0.6 U/kg body weight injected subcutaneously (under the skin) once
0.8 U/kg body weight injected subcutaneously (under the skin) once
Unnamed facility
Neuss, Germany
Area under the glucose infusion rate curve (only for IDegAsp)
Time frame: From 0 to 24 hours after single-dose
Area under the insulin aspart concentration-time curve
Time frame: From 0 to 12 hours after single-dose administration
Area under the insulin aspart concentration-time curve (only for BIAsp 30)
Time frame: From 0 to 24 hours after single-dose administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
0.4 U/kg body weight injected subcutaneously (under the skin) once
0.6 U/kg body weight injected subcutaneously (under the skin) once
0.8 U/kg body weight injected subcutaneously (under the skin) once